
Kojic Acid: May help uneven pigmentation, often as part of a combination treatment. Tranexamic Acid: Topical formulas are studied for melasma, with mixed results.


Consider for uneven pigment if tolerated; evidence is mainly for combinations.
Consider a topical pigment option; the evidence is mixed and formula-specific.
Can you use both?
A useful pairing for dark spots and melasma.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Reduces tyrosinase activity: Kojic acid interferes with melanin production. Less new pigment forms: Effects depend on the formula and tolerance.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Kojic acid concentrations in older studies differ from current cosmetic limits. In the EU, kojic acid is limited to 1% in face and hand products; that is not a universal treatment target.
1%
2%
EU cosmetic ceiling
The maximum in specified face and hand products. This is a regulatory limit, not proof of the best efficacy.
Older combination-study strength
Studied with hydroquinone and glycolic acid. The combination result does not isolate kojic acid or establish a current home-use recommendation.
Choosing a strength: Check local rules and the full formula. Kojic acid and kojic dipalmitate are different ingredients and cannot be compared by percentage alone.
Higher strengths: Do not use an older trial’s concentration as a reason to exceed current limits. Irritation or allergic contact dermatitis can occur.
Formula matters: Combination products may obtain benefit from several ingredients. A study of a combination cannot tell you what kojic acid alone contributed.
Topical tranexamic acid studies have used different delivery systems, including 1.8% liposomal lotion and 5% creams or solutions. Oral treatment and procedure-assisted delivery are separate medical decisions.
1.8%
5%
Studied liposomal lotion
One melasma trial tested this delivery system. Its percentage cannot be directly compared with an ordinary serum.
Studied topical formulas
Several melasma studies used topical formulas at this strength. Evidence does not establish one best concentration for all pigment concerns.
Choosing a strength: Look for evidence on the finished topical product. Do not use injectable or oral products as DIY skincare.
Higher strengths: A stronger topical percentage has not been shown to guarantee better results. Oral use requires separate evaluation of risks, including clotting risk.
Formula matters: Liposomal delivery, other brightening ingredients and procedures can change the treatment. A microneedling study is not evidence for the same result from a home serum.
Approximate windows, not promises.
First few weeksAssess tolerance first; pigment change is usually slower.
First few weeksAssess tolerance first; pigment change is usually slower.
4–8 weeksSome studied regimens begin showing pigment improvement.
4–8 weeksSome studied regimens begin showing pigment improvement.
8–12 weeksA useful review point for benefit and irritation.
8–12 weeksA useful review point for benefit and irritation.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
Can cause stinging, redness or contact dermatitis.
Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
There is not much pregnancy-specific data on kojic acid, and melasma often appears or worsens in pregnancy. Ask the doctor managing your pregnancy first. Azelaic acid and strict sun protection are the usual alternatives.
Melasma is common in pregnancy, so this comes up constantly. Oral tranexamic acid is not a casual pregnancy decision, and the topical version has little pregnancy-specific data. Ask the doctor managing your pregnancy, since they know your full picture.
On the skin. The finished product delivers kojic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Inhibits tyrosinase activity involved in melanin production; cosmetic formulas differ from studied combinations.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers tranexamic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. May affect plasmin-related signalling involved in pigmentation; a small molecular size does not guarantee delivery.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Consider for uneven pigment if tolerated; evidence is mainly for combinations.
A 40-woman split-face trial added kojic acid to hydroquinone and glycolic acid. It does not show that kojic acid alone performs as well as the combination or that higher strengths are better.
Consider a topical pigment option; the evidence is mixed and formula-specific.
A small vehicle-controlled 5% trial did not show superiority over vehicle. A larger active-comparator study found improvement in both groups but did not prove equivalence to hydroquinone.
Sources